Effects of Inspiratory Muscle Training (IMT) on Balance Ability and Quality of Life of Diabetes Mellitus Patients
Launched by RIPHAH INTERNATIONAL UNIVERSITY · Jun 30, 2021
Trial Information
Current as of August 19, 2025
Completed
Keywords
ClinConnect Summary
Diabetes Mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia due to either deficiency of insulin or the inability of the body to utilize it. Hyperglycemia ultimately leads to multiple organ damage in patients with uncontrolled diabetes. The incidence occurs mostly at the age of 55 years equally affecting both genders. The prevalence of diabetes has been increased four times in the last three decades worldwide and global prevalence is increasing alarmingly with about 1 out of every 11 individuals having diabetes mellitus with 90% patients having type 2 diabetes mellit...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mini Mental State Examination (MMSE) score \>24
- • Type II diabetes: Post 5-8 years diagnosis
- • Berg Balance score (30-40)
- • Presence of polyneuropathy confirmed through Modified Toronto Clinical Scoring System.
- Exclusion Criteria:
- • Patients on oxygen therapy
- • Uncontrolled diabetes (Confirmed through HbA1C) or disease exacerbation in last 3 months.
- • Patients practicing regular physical activity, any balance training in the last 6 months and previous or current experience with IMT
- • Patients with musculoskeletal comorbidities that may impair exercise performance
- • Peripheral oxygen saturation (SpO2) \< 90% during the Six-Minute Walk Test (6MWT)
- • Patients with long COVID syndrome
- • Hypertensive subjects without control medication as well as those presenting with a hypertensive peak (\> 140/90 mmHg) for more than 3 consecutive days
- • Patients with cardiorespiratory diseases or patients taking drugs that effect balance e.g., beta blockers, anti-anxiety and anti-depressant drugs.
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rawalpindi, Punjab, Pakistan
Patients applied
Trial Officials
Arshad Nawaz Malik, PhD
Principal Investigator
Riphah International University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials